BUCHANG PHARMA(SH:603858) Xin Lang Zheng Quan·2026-01-05 01:29Core Viewpoint - The financial performance and trading activity of Shandong Buchang Pharmaceutical Co., Ltd. indicate a mixed outlook, with a decline in revenue but a significant increase in net profit, alongside low financing and margin trading levels [1][2]. Group 1: Financial Performance - As of September 30, 2025, Buchang Pharmaceutical reported a revenue of 8.469 billion yuan, a year-on-year decrease of 0.54% [2]. - The net profit attributable to shareholders reached 868 million yuan, showing a substantial year-on-year increase of 177.54% [2]. - Cumulative cash dividends since the company's A-share listing amount to 7.948 billion yuan, with 1.609 billion yuan distributed over the past three years [2]. Group 2: Trading Activity - On December 31, 2025, Buchang Pharmaceutical's stock price fell by 0.38%, with a trading volume of 78.8184 million yuan [1]. - The financing buy amount for the day was 8.0737 million yuan, while the financing repayment was 12.3316 million yuan, resulting in a net financing outflow of 4.258 million yuan [1]. - The total margin trading balance stood at 518 million yuan, with the financing balance accounting for 3.13% of the circulating market value, indicating a low level compared to the past year [1]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders decreased to 51,100, a reduction of 7.36% [2]. - The average number of circulating shares per shareholder increased by 2.92% to 20,641 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 20.3871 million shares, an increase of 8.5127 million shares compared to the previous period [2].